Success and Need for Curettage in Outpatient and Inpatient Treatment of First Trimester Abortions with Misoprostol

Document Type : Original Article

Authors

1 Associate Professor, Department of Obstetrics and Gynecology, Family and Youth Support Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 General Physician, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Professor, Department of Obstetrics and Gynecology, Family and Youth Support Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Assistant Professor, Department of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

10.22038/ijogi.2025.76172.5913

Abstract

Introduction: The use of misoprostol tablet is a common method for the medical treatment of abortion. The present study was conducted with aim to compare success and need for curettage in outpatient and inpatient treatment of first trimester abortions with misoprostol.
Methods: This randomized clinical trial study was conducted on 142 pregnant women with diagnosis of miscarriage ≤14 weeks referred to Qaem Hospital in Mashhad from 2018 to 2020. The patients were divided into two groups of inpatient and outpatient. In both groups, 800 µg of vaginal and sublingual misoprostol were administered with the same dose and repeated if needed at similar intervals. The rate of complete elimination and the need for curettage were compared in two groups. Data were analyzed using SPSS statistical software (version 19). P<0.05 was considered significant.
Results: There was no significant difference in the percentage of curettage between the two groups (p=0.813). In terms of complications, fever (p=0.016), chills (p<0.001), and nausea and vomiting (p=0.049) were significantly higher in the outpatient group, but the rate of diarrhea was not significantly different between the two groups (p=0.722).
Conclusion: Termination of pregnancy in first trimester abortions using vaginal and sublingual misoprostol as an outpatient is a safe and effective method. This procedure requires no hospitalization and high hospital costs, and all procedures can be performed on an outpatient basis and can be a good alternative to inpatient method.

Keywords

Main Subjects

References

  1. Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Best practice & research Clinical obstetrics & gynaecology 2000; 14(5):839-54.
  2. Cardoso RM, Cardoso PL, Azevedo AP, Cadillá JS, Amorim MG, Gomes ME, et al. First-trimester miscarriage: A histopathological classification proposal. Heliyon 2021; 7(3).
  3. Goddijn M, Leschot NJ. Genetic aspects of miscarriage. Best Practice & Research Clinical Obstetrics & Gynaecology 2000; 14(5):855-65.
  4. Gracia CR, Sammel MD, Chittams J, Hummel AC, Shaunik A, Barnhart KT. Risk factors for spontaneous abortion in early symptomatic first-trimester pregnancies. Obstetrics & Gynecology 2005; 106(5 Part 1):993-9.
  5. Feodor Nilsson S, Andersen PK, Strandberg‐Larsen K, Nybo Andersen AM. Risk factors for miscarriage from a prevention perspective: a nationwide follow‐up study. BJOG: An International Journal of Obstetrics & Gynaecology 2014; 121(11):1375-85.
  6. Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage—results from a UK‐population‐based case–control study. BJOG: An International Journal of Obstetrics & Gynaecology 2007; 114(2):170-86.
  7. Ayati S, Vahidroodsari F, Amini M, Shakeri MT, Hasanzadeh M, Barhemat A. Vaginal and sublingual misoprostol for termination at second trimester pregnancy in patients with previous cesarean section. Iranian Journal of Obstetrics, Gynecology & Infertility 2012; 15(24).
  8. Cubo Nava A, Soto Pino ZM, Haro Pérez AM, Hernández Hernández ME, Doyague Sánchez MJ, Sayagués Manzano JM. Medical versus surgical treatment of first trimester spontaneous abortion: A cost-minimization analysis. PloS one 2019; 14(1):e0210449.
  9. Hendriks E, MacNaughton H, MacKenzie MC. First trimester bleeding: evaluation and management. American family physician 2019; 99(3):166-74.
  10. Jurkovic D, Overton C, Bender-Atik R. Diagnosis and management of first trimester miscarriage. Bmj 2013; 346.
  11. Ng BK, Annamalai R, Lim PS, Aqmar Suraya S, Nur Azurah AG, Muhammad Abdul Jamil MY. Outpatient versus inpatient intravaginal misoprostol for the treatment of first trimester incomplete miscarriage: a randomised controlled trial. Archives of gynecology and obstetrics 2015; 291(1):105-13.
  12. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstetrics & Gynecology 1997; 90(1):88-92.
  13. Diedrich J, Steinauer J. Complications of surgical abortion. Clinical obstetrics and gynecology 2009; 52(2):205-12.
  14. Ngoc NT, Blum J, Westheimer E, Quan TT, Winikoff B. Medical treatment of missed abortion using misoprostol. International Journal of Gynecology & Obstetrics 2004; 87(2):138-42.
  15. Allen R, O’Brien BM. Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics and gynecology 2009; 2(3):159.
  16. Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Journal of family practice 1997; 44(4):353-61.
  17. Shankar M, Economides DL, Sabin CA, Tan B, Kadir RA. Outpatient medical management of missed miscarriage using misoprostol. Journal of obstetrics and gynaecology 2007; 27(3):283-6.
  18. Smith PS, Peña M, Dzuba IG, Martinez ML, Peraza AG, Bousiéguez M, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reproductive health matters 2015; 22(44):75-82.
  19. Tan YL, Singh K, Tan KH, Gosavi A, Koh D, Abbas D, et al. Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore. European Journal of Obstetrics & Gynecology and Reproductive Biology 2018; 229:144-7.
  20. Hsia JK, Lohr PA, Taylor J, Creinin MD. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation. Contraception 2019; 100(3):178-81.
  21. Bracken H, Dabash R, Tsertsvadze G, Posohova S, Shah M, Hajri S, et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days' LMP: a prospective comparative open-label trial. Contraception 2014; 89(3):181-6.
  22. Dzuba IG, Chong E, Hannum C, Lichtenberg ES, Hernández EM, Patel A, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64–70 days and 71–77 days of gestation. Contraception 2020; 101(5):302-8.
  23. Barcelo F, De Paco C, López‐Espín JJ, Silva Y, Abad L, Parrilla JJ. The management of missed miscarriage in an outpatient setting: 800 versus 600 μg of vaginal misoprostol. Australian and New Zealand Journal of Obstetrics and Gynaecology 2012; 52(1):39-43.
  24. Abdullah ZB, Al-Jassim NH. Medical Treatment of Early Missed Miscarriage and Anembryonic Pregnancies: A Prospective Study of Outpatient Management Using Misoprostol Alone. Basrah Journal of Surgery 2016; 22(2):100-4.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 28, Issue 5
July 2025
Pages 9-18

Files

Share

How to cite

Statistics